can you please creat a high quality proffesional medical power point presentation based on the following plan: Slide 1 — Title • Neurofibromatosis: Clinical, Molecular, and Oncologic Perspectives • Presenter name, institution, date • Background image: schematic of RAS/MAPK pathway or café au lait macules Slide 2 — Learning Objectives • Understand the genetic basis and pathophysiology of NF1, NF2, and Schwannomatosis • Recognize key clinical manifestations relevant to oncology • Review tumor spectrum and malignant transformation risks • Discuss modern diagnostic criteria and surveillance guidelines • Evaluate current and emerging therapeutic strategies • Case based discussion of complex NF oncology scenarios 🧬 Section 1 — Overview & Genetics Slide 3 — What is Neurofibromatosis? • Definition • Classification: NF1, NF2 related schwannomatosis, SMARCB1/LZTR1 related schwannomatosis • Epidemiology (NF1 ~1:3000; NF2 ~1:25,000) Slide 4 — Genetics & Molecular Biology • NF1 gene → neurofibromin → negative regulator of RAS/MAPK • NF2 gene → merlin → tumor suppressor in Hippo pathway • Schwannomatosis genes → SMARCB1, LZTR1 • Germline vs somatic mosaicism • Two hit hypothesis (Knudson) Slide 5 — Pathophysiology • Loss of tumor suppressor → uncontrolled Schwann cell proliferation • Microenvironment: mast cells, fibroblasts, collagen deposition • Mechanism of plexiform neurofibroma formation • Merlin deficiency → meningioma & schwannoma biology 🩺 Section 2 — Clinical Manifestations Slide 6 — NF1 Diagnostic Criteria (2021 Update) • Café au lait macules • Axillary/inguinal freckling • Neurofibromas (cutaneous, subcutaneous, plexiform) • Optic pathway glioma • Lisch nodules • Osseous lesions • Pathogenic NF1 variant Slide 7 — NF1 Tumor Spectrum • Plexiform neurofibromas • Cutaneous neurofibromas • Optic pathway gliomas • Malignant peripheral nerve sheath tumors (MPNST) • GIST, pheochromocytoma, breast cancer (early onset) Slide 8 — NF2 Clinical Features • Bilateral vestibular schwannomas (hallmark) • Meningiomas • Ependymomas • Peripheral schwannomas • Cataracts & ocular findings Slide 9 — Schwannomatosis • Painful schwannomas • Absence of vestibular schwannomas • Genetic subtypes: SMARCB1, LZTR1 • Mosaic forms 🧠 Section 3 — Tumors of Oncologic Importance Slide 10 — Plexiform Neurofibroma • Natural history • Imaging characteristics (T2 hyperintense “target sign”) • Risk of malignant transformation • Surgical challenges Slide 11 — MPNST • Epidemiology in NF1 • Clinical red flags: rapid growth, pain, neurological deficit • MRI + PET features • Histopathology • Prognosis • Management: surgery, radiotherapy, chemotherapy Slide 12 — Optic Pathway Glioma • Pediatric predominance • Symptoms • MRI patterns • Treatment: observation vs chemotherapy (vincristine/carboplatin) • Role of MEK inhibitors Slide 13 — NF2 Associated Tumors • Vestibular schwannoma • Meningioma • Spinal ependymoma • Treatment strategies: surgery, radiosurgery, bevacizumab 🧪 Section 4 — Diagno
can you please creat a high quality proffesional medical power point presentation based on the following plan: Slide 1 — Title • Neurofibromatosis: Clinical, Molecular, and Oncologic Perspectives • Presenter name, institution, date • Background image: schematic of RAS/MAPK pathway or café au lait macules Slide 2 — Learning Objectives • Understand the genetic basis and pathophysiology of NF1, NF2, and Schwannomatosis • Recognize key clinical manifestations relevant to oncology • Review tumor spectrum and malignant transformation risks • Discuss modern diagnostic criteria and surveillance guidelines • Evaluate current and emerging therapeutic strategies • Case based discussion of complex NF oncology scenarios 🧬 Section 1 — Overview & Genetics Slide 3 — What is Neurofibromatosis? • Definition • Classification: NF1, NF2 related schwannomatosis, SMARCB1/LZTR1 related schwannomatosis • Epidemiology (NF1 ~1:3000; NF2 ~1:25,000) Slide 4 — Genetics & Molecular Biology • NF1 gene → neurofibromin → negative regulator of RAS/MAPK • NF2 gene → merlin → tumor suppressor in Hippo pathway • Schwannomatosis genes → SMARCB1, LZTR1 • Germline vs somatic mosaicism • Two hit hypothesis (Knudson) Slide 5 — Pathophysiology • Loss of tumor suppressor → uncontrolled Schwann cell proliferation • Microenvironment: mast cells, fibroblasts, collagen deposition • Mechanism of plexiform neurofibroma formation • Merlin deficiency → meningioma & schwannoma biology 🩺 Section 2 — Clinical Manifestations Slide 6 — NF1 Diagnostic Criteria (2021 Update) • Café au lait macules • Axillary/inguinal freckling • Neurofibromas (cutaneous, subcutaneous, plexiform) • Optic pathway glioma • Lisch nodules • Osseous lesions • Pathogenic NF1 variant Slide 7 — NF1 Tumor Spectrum • Plexiform neurofibromas • Cutaneous neurofibromas • Optic pathway gliomas • Malignant peripheral nerve sheath tumors (MPNST) • GIST, pheochromocytoma, breast cancer (early onset) Slide 8 — NF2 Clinical Features • Bilateral vestibular schwannomas (hallmark) • Meningiomas • Ependymomas • Peripheral schwannomas • Cataracts & ocular findings Slide 9 — Schwannomatosis • Painful schwannomas • Absence of vestibular schwannomas • Genetic subtypes: SMARCB1, LZTR1 • Mosaic forms 🧠 Section 3 — Tumors of Oncologic Importance Slide 10 — Plexiform Neurofibroma • Natural history • Imaging characteristics (T2 hyperintense “target sign”) • Risk of malignant transformation • Surgical challenges Slide 11 — MPNST • Epidemiology in NF1 • Clinical red flags: rapid growth, pain, neurological deficit • MRI + PET features • Histopathology • Prognosis • Management: surgery, radiotherapy, chemotherapy Slide 12 — Optic Pathway Glioma • Pediatric predominance • Symptoms • MRI patterns • Treatment: observation vs chemotherapy (vincristine/carboplatin) • Role of MEK inhibitors Slide 13 — NF2 Associated Tumors • Vestibular schwannoma • Meningioma • Spinal ependymoma • Treatment strategies: surgery, radiosurgery, bevacizumab 🧪 Section 4 — Diagno
Created using ChatSlide
This comprehensive overview covers the foundations of neurofibromatosis types 1, 2, and schwannomatosis, detailing their classification, prevalence, and implications for oncology. It emphasises clinical recognition through updated diagnostic criteria and highlights key tumour characteristics requiring oncologic attention. The strategy for diagnosis and surveillance integrates advanced imaging and multidisciplinary approaches, distinguishing between observation and active treatment. Finally,...